Please wait while the formulary information is being retrieved.
Drug overview for ALBUKED-25 (albumin human):
Generic name: ALBUMIN HUMAN
Drug class: Plasma Proteins
Therapeutic class: Hematological Agents
Albumin human, a protein colloid, is a sterile solution of serum albumin prepared by fractionating pooled plasma from healthy human donors.
No enhanced Uses information available for this drug.
Generic name: ALBUMIN HUMAN
Drug class: Plasma Proteins
Therapeutic class: Hematological Agents
Albumin human, a protein colloid, is a sterile solution of serum albumin prepared by fractionating pooled plasma from healthy human donors.
No enhanced Uses information available for this drug.
DRUG IMAGES
No Image Available
The following indications for ALBUKED-25 (albumin human) have been approved by the FDA:
Indications:
Acute hepatic failure
Hyperbilirubinemia due to hemolytic disease of newborn
Hypoalbuminemia
Hypovolemic shock
Severe burns
Professional Synonyms:
Decreased serum albumin
Hyperbilirubinemia due to erythroblastosis fetalis
Hyperbilirubinemia due to HDN (hemolytic disease of newborn)
Hyperbilirubinemia in hemolytic disease of newborn from isoimmunization
Hypovolemic shock syndrome
Severe burn injuries
Indications:
Acute hepatic failure
Hyperbilirubinemia due to hemolytic disease of newborn
Hypoalbuminemia
Hypovolemic shock
Severe burns
Professional Synonyms:
Decreased serum albumin
Hyperbilirubinemia due to erythroblastosis fetalis
Hyperbilirubinemia due to HDN (hemolytic disease of newborn)
Hyperbilirubinemia in hemolytic disease of newborn from isoimmunization
Hypovolemic shock syndrome
Severe burn injuries
The following dosing information is available for ALBUKED-25 (albumin human):
Dosage of albumin human is variable and should be individualized based on the specific indication, concentration of albumin human solution used, and clinical status and response of the patient. The manufacturers' information should be consulted for specific dosage recommendations.
Predetermined formulas for dosage calculation generally are avoided since they assume that the same dose is appropriate for all patients. In the absence of active hemorrhage, total daily albumin dosage should not exceed the theoretical amount present in normal plasma volume (i.e., 2 g/kg body weight).
Response to therapy should be determined by factors such as hemodynamic response (e.g., blood pressure), degree of pulmonary congestion, and hematocrit. Serum protein concentrations usually do not need to be monitored during albumin human therapy, but may be useful in some cases of hypoproteinemia to estimate the total body albumin deficit and guide selection of dosage.
Osmotic Equivalence of Commercially Available Albumin Human Injections for IV Infusion
Albumin human injection for IV Osmotic equivalence infusion 100 mL of 5% solution (5 g) 100 mL of normal human plasma 100 mL of 20% solution (20 g) 400 mL of normal human plasma 100 mL of 25% solution (25 g) 500 mL of normal human plasma
Predetermined formulas for dosage calculation generally are avoided since they assume that the same dose is appropriate for all patients. In the absence of active hemorrhage, total daily albumin dosage should not exceed the theoretical amount present in normal plasma volume (i.e., 2 g/kg body weight).
Response to therapy should be determined by factors such as hemodynamic response (e.g., blood pressure), degree of pulmonary congestion, and hematocrit. Serum protein concentrations usually do not need to be monitored during albumin human therapy, but may be useful in some cases of hypoproteinemia to estimate the total body albumin deficit and guide selection of dosage.
Osmotic Equivalence of Commercially Available Albumin Human Injections for IV Infusion
Albumin human injection for IV Osmotic equivalence infusion 100 mL of 5% solution (5 g) 100 mL of normal human plasma 100 mL of 20% solution (20 g) 400 mL of normal human plasma 100 mL of 25% solution (25 g) 500 mL of normal human plasma
Albumin human solutions are administered by IV infusion. The concentration of albumin human administered (i.e., albumin human 5, 20, or 25% solution) depends on the fluid and protein requirements of the patient and is determined in part by whether there is a greater need for volume or oncotic replacement. Albumin human 5% solutions usually are preferred in the treatment of acute blood volume deficits in the absence of adequate or excessive hydration.
Albumin human 20 or 25% solutions may be preferred when there is an oncotic deficit or when hypovolemia is long standing (e.g., due to treatment delay) and hypoalbuminemia exists in the presence of adequate or excessive hydration. Albumin human 20 or 25% solutions also are preferred when the drug is being used for its binding rather than oncotic effects (e.g., in the treatment of neonatal hyperbilirubinemia). When used for the treatment of hypovolemia, albumin human solutions are most effective in well-hydrated patients. If the patient is dehydrated, albumin human 5% solution usually is preferred; if albumin human 20 or 25% solutions are used in dehydrated patients, additional crystalloids or other fluids should be administered.
Albumin human 20 or 25% solutions may be preferred when there is an oncotic deficit or when hypovolemia is long standing (e.g., due to treatment delay) and hypoalbuminemia exists in the presence of adequate or excessive hydration. Albumin human 20 or 25% solutions also are preferred when the drug is being used for its binding rather than oncotic effects (e.g., in the treatment of neonatal hyperbilirubinemia). When used for the treatment of hypovolemia, albumin human solutions are most effective in well-hydrated patients. If the patient is dehydrated, albumin human 5% solution usually is preferred; if albumin human 20 or 25% solutions are used in dehydrated patients, additional crystalloids or other fluids should be administered.
No dosing information available.
No generic dosing information available.
The following drug interaction information is available for ALBUKED-25 (albumin human):
There are 0 contraindications.
There are 0 severe interactions.
There are 0 moderate interactions.
The following contraindication information is available for ALBUKED-25 (albumin human):
Drug contraindication overview.
No enhanced Contraindications information available for this drug.
No enhanced Contraindications information available for this drug.
There are 0 contraindications.
There are 7 severe contraindications.
Adequate patient monitoring is recommended for safer drug use.
| Severe List |
|---|
| Anuria |
| Cardiac decompensation |
| Esophageal varices |
| Hypervolemia |
| Increased risk of bleeding |
| Pulmonary edema |
| Severe anemia |
There are 1 moderate contraindications.
Clinically significant contraindication, where the condition can be managed or treated before the drug may be given safely.
| Moderate List |
|---|
| Hypertension |
The following adverse reaction information is available for ALBUKED-25 (albumin human):
Adverse reaction overview.
No enhanced Common Adverse Effects information available for this drug.
No enhanced Common Adverse Effects information available for this drug.
There are 7 severe adverse reactions.
| More Frequent | Less Frequent |
|---|---|
|
Dyspnea Hypotension |
Chronic heart failure Pulmonary edema |
| Rare/Very Rare |
|---|
|
Anaphylaxis Cardiac arrhythmia Respiratory depression |
There are 11 less severe adverse reactions.
| More Frequent | Less Frequent |
|---|---|
|
Chills Fever Nausea Pruritus of skin Skin rash Tachycardia Vomiting |
Body fluid retention Edema |
| Rare/Very Rare |
|---|
|
Sialorrhea Urticaria |
The following precautions are available for ALBUKED-25 (albumin human):
No enhanced Pediatric Use information available for this drug.
Contraindicated
Severe Precaution
Management or Monitoring Precaution
Contraindicated
| None |
Severe Precaution
| None |
Management or Monitoring Precaution
| None |
Animal reproduction studies have not been performed with albumin human. It is not known whether albumin human can cause fetal harm when administered during pregnancy or during labor or delivery. Potential risks and benefits for the specific patient should be considered, and albumin human should be used in pregnant women or during labor and delivery only if clearly needed. One manufacturer states that there is no evidence for any contraindications specifically associated with reproduction, pregnancy, or the fetus.
It is not known whether albumin human is distributed into milk. Albumin human should be used with caution in breast-feeding women and only when clearly needed.
No enhanced Geriatric Use information available for this drug.
The following prioritized warning is available for ALBUKED-25 (albumin human):
No warning message for this drug.
No warning message for this drug.
The following icd codes are available for ALBUKED-25 (albumin human)'s list of indications:
| Acute hepatic failure | |
| K72.0 | Acute and subacute hepatic failure |
| K72.00 | Acute and subacute hepatic failure without coma |
| K72.01 | Acute and subacute hepatic failure with coma |
| Hyperbilirubinemia due to hemolytic disease of newborn | |
| P55 | Hemolytic disease of newborn |
| P55.0 | Rh isoimmunization of newborn |
| P55.1 | ABO isoimmunization of newborn |
| P55.8 | Other hemolytic diseases of newborn |
| P55.9 | Hemolytic disease of newborn, unspecified |
| P58.9 | Neonatal jaundice due to excessive hemolysis, unspecified |
| Hypoalbuminemia | |
| E88.09 | Other disorders of plasma-protein metabolism, not elsewhere classified |
| Hypovolemic shock | |
| R57.1 | Hypovolemic shock |
| Severe burns | |
| L55.2 | Sunburn of third degree |
| T31.0 | Burns involving less than 10% of body surface |
| T31.1 | Burns involving 10-19% of body surface |
| T31.10 | Burns involving 10-19% of body surface with 0% to 9% third degree burns |
| T31.11 | Burns involving 10-19% of body surface with 10-19% third degree burns |
| T31.2 | Burns involving 20-29% of body surface |
| T31.20 | Burns involving 20-29% of body surface with 0% to 9% third degree burns |
| T31.21 | Burns involving 20-29% of body surface with 10-19% third degree burns |
| T31.22 | Burns involving 20-29% of body surface with 20-29% third degree burns |
| T31.3 | Burns involving 30-39% of body surface |
| T31.30 | Burns involving 30-39% of body surface with 0% to 9% third degree burns |
| T31.31 | Burns involving 30-39% of body surface with 10-19% third degree burns |
| T31.32 | Burns involving 30-39% of body surface with 20-29% third degree burns |
| T31.33 | Burns involving 30-39% of body surface with 30-39% third degree burns |
| T31.4 | Burns involving 40-49% of body surface |
| T31.40 | Burns involving 40-49% of body surface with 0% to 9% third degree burns |
| T31.41 | Burns involving 40-49% of body surface with 10-19% third degree burns |
| T31.42 | Burns involving 40-49% of body surface with 20-29% third degree burns |
| T31.43 | Burns involving 40-49% of body surface with 30-39% third degree burns |
| T31.44 | Burns involving 40-49% of body surface with 40-49% third degree burns |
| T31.5 | Burns involving 50-59% of body surface |
| T31.50 | Burns involving 50-59% of body surface with 0% to 9% third degree burns |
| T31.51 | Burns involving 50-59% of body surface with 10-19% third degree burns |
| T31.52 | Burns involving 50-59% of body surface with 20-29% third degree burns |
| T31.53 | Burns involving 50-59% of body surface with 30-39% third degree burns |
| T31.54 | Burns involving 50-59% of body surface with 40-49% third degree burns |
| T31.55 | Burns involving 50-59% of body surface with 50-59% third degree burns |
| T31.6 | Burns involving 60-69% of body surface |
| T31.60 | Burns involving 60-69% of body surface with 0% to 9% third degree burns |
| T31.61 | Burns involving 60-69% of body surface with 10-19% third degree burns |
| T31.62 | Burns involving 60-69% of body surface with 20-29% third degree burns |
| T31.63 | Burns involving 60-69% of body surface with 30-39% third degree burns |
| T31.64 | Burns involving 60-69% of body surface with 40-49% third degree burns |
| T31.65 | Burns involving 60-69% of body surface with 50-59% third degree burns |
| T31.66 | Burns involving 60-69% of body surface with 60-69% third degree burns |
| T31.7 | Burns involving 70-79% of body surface |
| T31.70 | Burns involving 70-79% of body surface with 0% to 9% third degree burns |
| T31.71 | Burns involving 70-79% of body surface with 10-19% third degree burns |
| T31.72 | Burns involving 70-79% of body surface with 20-29% third degree burns |
| T31.73 | Burns involving 70-79% of body surface with 30-39% third degree burns |
| T31.74 | Burns involving 70-79% of body surface with 40-49% third degree burns |
| T31.75 | Burns involving 70-79% of body surface with 50-59% third degree burns |
| T31.76 | Burns involving 70-79% of body surface with 60-69% third degree burns |
| T31.77 | Burns involving 70-79% of body surface with 70-79% third degree burns |
| T31.8 | Burns involving 80-89% of body surface |
| T31.80 | Burns involving 80-89% of body surface with 0% to 9% third degree burns |
| T31.81 | Burns involving 80-89% of body surface with 10-19% third degree burns |
| T31.82 | Burns involving 80-89% of body surface with 20-29% third degree burns |
| T31.83 | Burns involving 80-89% of body surface with 30-39% third degree burns |
| T31.84 | Burns involving 80-89% of body surface with 40-49% third degree burns |
| T31.85 | Burns involving 80-89% of body surface with 50-59% third degree burns |
| T31.86 | Burns involving 80-89% of body surface with 60-69% third degree burns |
| T31.87 | Burns involving 80-89% of body surface with 70-79% third degree burns |
| T31.88 | Burns involving 80-89% of body surface with 80-89% third degree burns |
| T31.9 | Burns involving 90% or more of body surface |
| T31.90 | Burns involving 90% or more of body surface with 0% to 9% third degree burns |
| T31.91 | Burns involving 90% or more of body surface with 10-19% third degree burns |
| T31.92 | Burns involving 90% or more of body surface with 20-29% third degree burns |
| T31.93 | Burns involving 90% or more of body surface with 30-39% third degree burns |
| T31.94 | Burns involving 90% or more of body surface with 40-49% third degree burns |
| T31.95 | Burns involving 90% or more of body surface with 50-59% third degree burns |
| T31.96 | Burns involving 90% or more of body surface with 60-69% third degree burns |
| T31.97 | Burns involving 90% or more of body surface with 70-79% third degree burns |
| T31.98 | Burns involving 90% or more of body surface with 80-89% third degree burns |
| T31.99 | Burns involving 90% or more of body surface with 90% or more third degree burns |
Formulary Reference Tool